Precision approach in apoA-I infusion trials: When CSL112 may actually work.

In the recent ApoA-I Event Reducing in Ischemic Syndromes II trial, a plasma-derived apolipoprotein A-I (apoA-I) infusion (CSL112) demonstrated no significant reduction in major cardiovascular events in the overall postmyocardial infarction population. However, exploratory analyses revealed benefits in subgroups with both elevated low-density lipoprotein cholesterol (LDL-C) and systemic inflammation, suggesting that biologic context may be critical to therapeutic efficacy. Building on these trial findings, we highlight that the efficacy of CSL112 may depend on the coexistence of elevated LDL-C and systemic inflammation. We integrate ATP-binding cassette transporter A1 (ABCA1) biology with subgroup trial findings to propose a precision-stratification framework for future apoA-I infusion trials. We focus on the interaction of lipid burden and inflammation on ABCA1 transporter function, the impact of statin-induced transporter downregulation, and strategies for patient selection, including ex vivo efflux assays and molecular transporter profiling, and the therapeutic promise of combination therapies (apoA-I infusion with liver X receptor agonists) in patients with impaired transporter function.

• Publication year

  2025

• Venue

  Journal of Clinical Lipidology

• Publication date

  2025-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacl.2025.12.015PMID 41545247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels

  2025cited by this paper
• Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.

  2024cited by this paper
• Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport.

  2020cited by this paper
• Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High-Density Lipoprotein

  2015cited by this paper
• Cholesterol, inflammation and innate immunity

  2015cited by this paper
• HDL cholesterol efflux capacity and incident cardiovascular events.

  2014cited by this paper
• Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux

  2013cited by this paper
• Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks

  2013cited by this paper
• Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

  2011cited by this paper
• Reduced Expression of ATP-Binding Cassette Transporter G1 Increases Cholesterol Accumulation in Macrophages of Patients With Type 2 Diabetes Mellitus

  2008cited by this paper
• The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation.

  2008cited by this paper
• Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDLs⃞ Published, JLR Papers in Press, March 19, 2007.

  2007cited by this paper
• Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha.

  2000cited by this paper

• No citing papers are available for this paper.